Corient Private Wealth LLC Buys 291,425 Shares of Kenvue Inc. (NYSE:KVUE)

Corient Private Wealth LLC increased its stake in shares of Kenvue Inc. (NYSE:KVUE) by 601.8% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 339,848 shares of the company’s stock after acquiring an additional 291,425 shares during the period. Corient Private Wealth LLC’s holdings in Kenvue were worth $7,256,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in the stock. Grove Bank & Trust raised its stake in shares of Kenvue by 438.4% in the 4th quarter. Grove Bank & Trust now owns 1,163 shares of the company’s stock valued at $25,000 after purchasing an additional 947 shares during the period. Geneos Wealth Management Inc. bought a new position in shares of Kenvue during the fourth quarter worth about $29,000. SRS Capital Advisors Inc. raised its position in Kenvue by 67.4% in the 4th quarter. SRS Capital Advisors Inc. now owns 1,418 shares of the company’s stock valued at $30,000 after buying an additional 571 shares during the last quarter. Fortitude Family Office LLC lifted its stake in Kenvue by 106.6% in the 4th quarter. Fortitude Family Office LLC now owns 1,506 shares of the company’s stock valued at $32,000 after acquiring an additional 777 shares in the last quarter. Finally, Versant Capital Management Inc boosted its position in Kenvue by 300.8% during the 4th quarter. Versant Capital Management Inc now owns 1,920 shares of the company’s stock worth $41,000 after acquiring an additional 1,441 shares during the last quarter. 97.64% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of analysts have recently issued reports on the stock. Royal Bank of Canada reiterated a “sector perform” rating and issued a $24.00 price objective on shares of Kenvue in a report on Monday, February 3rd. Barclays lowered their price target on shares of Kenvue from $23.00 to $21.00 and set an “equal weight” rating on the stock in a research note on Friday, January 17th. UBS Group reduced their price objective on shares of Kenvue from $23.00 to $21.00 and set a “neutral” rating for the company in a research note on Friday, February 7th. Citigroup lowered their target price on Kenvue from $25.00 to $21.00 and set a “neutral” rating on the stock in a research report on Wednesday, January 15th. Finally, Piper Sandler increased their price target on Kenvue from $24.00 to $27.00 and gave the company an “overweight” rating in a research report on Monday, February 24th. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating and five have given a buy rating to the stock. According to data from MarketBeat, Kenvue currently has an average rating of “Hold” and an average price target of $23.75.

Kenvue Stock Down 0.5 %

NYSE KVUE opened at $23.41 on Friday. Kenvue Inc. has a fifty-two week low of $17.67 and a fifty-two week high of $24.46. The business has a fifty day moving average price of $22.03 and a two-hundred day moving average price of $22.42. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.00 and a quick ratio of 0.69. The stock has a market capitalization of $44.74 billion, a PE ratio of 44.17, a PEG ratio of 2.62 and a beta of 1.25.

Kenvue (NYSE:KVUE) last released its quarterly earnings data on Thursday, February 6th. The company reported $0.26 earnings per share for the quarter, meeting the consensus estimate of $0.26. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. Equities analysts expect that Kenvue Inc. will post 1.14 earnings per share for the current fiscal year.

Kenvue Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, February 26th. Investors of record on Wednesday, February 12th were paid a $0.205 dividend. This represents a $0.82 annualized dividend and a yield of 3.50%. The ex-dividend date of this dividend was Wednesday, February 12th. Kenvue’s payout ratio is 154.72%.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.